RxDoctor Payments Data

Hoang Nguyen, MD

Family Medicine · Canoga Park, CANPI 1124011952

Payments from drug & device makers

$1,946in general payments, 2019–2025

Across 35 payments — averaging $55.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$314
  • AstraZeneca$263
  • Amarin Pharma, Inc.$261
  • Bayer$244
  • Merck$186
  • Amgen$165
  • plus $513 from 8 others

What the payments were for

  • Food & beverage$1,940100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,946 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$7,741
Medicare patients
22
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate131$131,888
JardianceEmpagliflozin117$127,183
TradjentaLinagliptin33$29,790
FarxigaDapagliflozin Propanediol23$24,527
Janumet XrSitagliptin Phos/Metformin Hcl14$13,939
OzempicSemaglutide11$11,885
Atorvastatin Calcium752$9,008
VascepaIcosapent Ethyl12$8,415
Valsartan295$6,902
Amlodipine Besylate592$5,305
Albuterol Sulfate HfaAlbuterol Sulfate87$4,859
Metoprolol Succinate187$4,112
Celecoxib78$3,466
Icosapent Ethyl17$3,262
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$314$156,973150 claims
MerckJanuvia, Janumet Xr$186$145,828145 claims
AstraZenecaFarxiga$263$24,52723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Canoga Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →